Introduction
Metabolites playasignificant role in the pharmacology and toxicityo fadrug. Most drugs are substrates for the hepatic P450 oxidases. Commonly,acompound is rendered less toxic, [1] with notable exceptions. [2] Metabolites can impose their own pharmacological, toxicological, andp hysiological effects, whichl ead to complications that have resulted in the withdrawal of severald rugs from the market in recent years, including iproniazid, troglitazone, benoxaprofen, phenfluramine, and pemoline. [3] For prodrugs, the metabolites are the efficacious species. Because of the potentialp harmacological activity and toxicityo fd rug metabolites, major metabolites must also be tested in ADME (absorption, distribution, metabolism, and excretion) studies. Testing is especially important if metabolites are present at high levels in plasma and tissues, and if human metabolites are not formed in animal models. [3, 4] Common reactions in drug metabolism involve regioselective oxidation of unactivated CÀHb onds, at ransformation which currently lacks ag eneral counterparti ns ynthetic organic chemistry.T herefore, drug metabolites usually cannotb e synthesized directly from the drug itself and require anew synthetic strategy.D irect preparation by using P450 enzymes is an attractive alternative. Hepatic microsomesa re as ource for many different P450 activities, but their availability is limited, and their enzyme expression levels often depend on prior inductionand exposure to xenobiotics. These limitations severely restrictt heir application for preparative synthesis of metabolites. Heterologous expression of human CYPs could be as olution. [5] Unfortunately,h uman P450s are membrane-bound and expressed at low levels, require two-component electron-transfer systems, ande xhibit low activity and stability. [6] Although many bacteria and fungi also perform am ammalian-like metabolism, many of these strains are uncharacterized and grow poorly in culture. [7] Ap otential solution is to clone the P450 genes from these strains into host organismst hat are more easily cultivated and then use these host organisms to produce relevant drug metabolites. [7] The bacterial P450 monooxygenase, P450 BM3 ,afatty acid hydroxylase isolated from Bacillus megaterium,h as ac ovalentl ink between its hydroxylase and diflavin reductase domains, is expressed at high levels in Escherichia coli, and exhibits very fast reactionr ates (thousands of turnovers per minute)o nf avored substrates. P450 BM3 can be engineered to accept av ariety of substrates, including drugs. We, and others, have demonstrated that P450 BM3 variants are capable of producing human metabolites of propanolol, [8] verapamil, astemizole, [9] 7-ethoxycoumarin, [10] chlorzoxazone, [11] amodiaquine, dextromethorphan, buspirone, and 3,4-methylenedioxymethyl-amphetamine (MDMA).
Simple and universal methods for the preparation of human drug metabolites are required to produce quantities sufficient for their characterization and toxicity testing. Synthetic chemistry lacks general catalysts for selectiveo xidation of unactivated CÀHb onds, at ransformation that plays ak ey role in metabolism;b ioconversions using P450 enzymes have emerged as a powerful alternative. VariantsofP 450 BM3 from Bacillusmegaterium act on diverse substrates, including drugs. Acidic substrates, such as the compounds metabolized by CYP2C9, which is one of three main hepatic human P450s, are not accepted by P450 BM3 variants engineered to date. Herein, we report bacterial mimics of CYP2C9, which are active on two widely administered drugs,n aproxen and ibuprofen, that are CYP2C9 substrates in vivo. These P450 BM3 variants can also act on desmethylnaproxen, the human metabolite of naproxen,a nd convert it to the 1,4-naphthoquinone derivative. We analyzed the crystal structure of the heme domain of an early intermediate in the directed-evolutione xperiment.T he active site mutation, L75R, which initially conferred activity on charged substrates, dramatically increaseds tructuralf lexibility in the B'-helix. This increased flexibility,w hich was accompanied by ad ramatic decrease in enzyme stability,m ay contributet ot he variant's ability to accept ab roader range of substrates.
To date, most of the drugs that can be metabolized by using P450 BM3 variantsa re substrates of human CYP3A4, CYP2E1, and CYP2D6. CYP3A4 and CYP2C9 are the two main hepatic P450s, constituting approximately 50 %o ft he total hepatic P450 protein, [13] and contribute to the metabolism of more than 60 %o fa ll drugs, based on available literature. [14] CYP2C9 alone is responsible for approximately 15 %o fk nown conversionsa nd has ap reference for substrates with weak acidity. [15] Many commonly used nonsteroidal anti-inflammatory drugs (NSAIDs), such as those of the profen family( naproxen, ibuprofen, flurbiprofen, ketoprofen) and diclofenac, have ac arboxyl moiety anda re substrates of CYP2C9. [16] There has been no report on aP 450 BM3 variant exhibiting good activity on these charged molecules. [7, 11] We aimed to address this shortcoming and extend the activity of P450 BM3 variants to weakly acidic drugs that fall into the substrate spectrum of human CYP2C9. Substrates chosen for this studyi nclude two widely applied NSAIDs, naproxen 1 and ibuprofen 5 (Scheme 1). We previously reported av ariant of the P450 BM3 heme domain with very low,b ut detectable, activity on naproxen. [17] This variant,t ermed 13C9, was found by using random mutagenesis and screening of 5H6, at hermostabilized, H 2 O 2 -driven hydroxylase (heme domain "peroxygenase" withoutt he reductase domain). With respectt o5 H6, variant 13C9 carried as ingle mutation at L75R, ap osition that has been shown to affect activity on short-chain carboxylic acids. [18] We hadh ypothesized that R75, in the substrate-binding pocket, allowed 13C9 to bind naproxen by providing ac ompensating positive charge for the naproxen carboxylate group. [17] It was possible that the R75 in helix B' interacted directly with the carboxylate group, but there was no experimental evidence to support this.
The goals of the current study were 1) to increasee nzyme turnover to al evel that would enable preparative-scale reactions [19] (TTN of at least 1000, with TTN = total turnover number = mol product per mol enzymec atalyst) by directed evolution of 13C9 and 2) to elucidate the structural basis for the broad tolerance for negatively-charged substrates caused by the L75R mutation. Therefore, we determined the crystal structure of 22A3, an early variant in the directed-evolution experiment carrying the L75R mutation and still showing broad substrate tolerance.
Results and Discussion
Directed evolution to generate aC YP2C9 functional mimic Analysis using HPLC and HPLC-MS confirmed that the human metabolite desmethylnaproxen 2 was the main product of the bioconversion of naproxen in the presence of the parent P450 BM3 variant 13C9 and peroxide ( Figure 1 , m/z = 215, TTN 8). Three aromatic hydroxylation products (m/z = 246, TTN % 1 each) were also found. Wild-type P450 BM3 showed no activity on naproxen ( Figure 1 ).
To improvet he TTN of 13C9 for desmethylnaproxen, we first reattached the reductase domain to obtain the efficient holoenzymeo fP 450 BM3 .R ebuilding the monooxygenase from the heme domain peroxygenase has been shown to improve the hydroxylase activityofP450 BM3 peroxygenase variants [20] and increasest he lifetime of the enzymeb ys ubstituting O 2 ,N ADPH, and ar egenerationsystem for the peroxide.
The reconstituted monooxygenase 13C9R1 indeed showed improved activity for the production of desmethylnaproxen (TTN 15, Figure 1 ) andp roduced am ixture of hydroxylated side products. 13C9R1 was subjected to five rounds of directed evolution toward higher yields of desmethylnaproxen. To test for improved demethylation activity,w eu sed the purpald screen, which detectst he formaldehyde released upon hydroxylation at the methoxy group. [21] We used error-prone polymerase chain reaction (PCR) to randomly mutate the DNA encoding the heme domain, with mutation rates between 1.5 and 6n ucleotides (nt) per gene, corresponding to an average of 0.3-3 amino acid substitutions (see the Supporting Information, Table S2 ). Variantse xhibiting higher demethylation activity usually contained 1-2 amino acid substitutions with respect to their parent (Table 1 , and Supporting Information, Ta ble S3). In one round (starting from 16G2), we did not find any improved variant upon screening approximately 3000 clones, but repeating the screen with a new random mutant libraryg ave improved variant W7D8. Figure 1B shows the course of the evolution, in terms of the relative activity in the purpald screen and the TTNs of bioconversions by using purified enzymes. Final variant X3H1 carried six mutationsw ith respect to 13C9R1 and exhibited ! 1000 TTN for the conversion of naproxen to desmethylnaproxen, corresponding to am ore than 60-fold improvement over the reconScheme1.P450-catalyzed oxidation of naproxen 1 and ibuprofen 5 by CYP2C9 and P450 BM3 variants. A) Demethylation (1) of naproxen by CYP2C9 yields desmethylnaproxen 2.P 450 BM3 variants, active on 1, were found to produce 4 in ac onsecutive reaction (2), presumablythrough as econd hydroxylation of 2 to 3 followed by anonenzymatic oxidation.B )Oxidative ibuprofen metabolism in humans produces 2-and 3-hydroxyibuprofens 6 and 7,r espectively. [22] P450 BM3 variants produce the same metabolites at different ratios (see Ta ble 1) . Reagents, conditions, and yields: 1) 1,X3H1 (1 mol %), 2 (43 %, isolatedyield);3 )5,W 7D8 (1 mol %), 6 (96 %, isolated yield).
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In the bioconversions, we also detected activity of the evolvedP 450 BM3 variants on ibuprofen 5,a nN SAID commonly administered for its anti-inflammatory,a nalgesic, and antipyretic properties. Ibuprofen is hydroxylated at positions 2( 6 )a nd 3 (7)b yh uman P450s CYP2C9 and CYP2C8 (Scheme 1). We previously reported that P450 BM3 variants were active on the methylester of ibuprofen and isolated products hydroxylated at positions 1a nd 2, [23] but ibuprofen itself was not as ubstrate. We now found that the activity on ibuprofen was concomitant with acquisition of activity on naproxen in the initial rounds of directede volution. Bioconversion of ibuprofen yieldedo ne major (6)a nd one minor (7)h ydroxylation product ( Figure 1A) . Interestingly,t he hydroxylation at position 1o ft he ibuprofen methyl ester was not observed, presumably because it would require further burial of the chargedg roup within the hydrophobic binding channel. By using the P450 BM3 variant W7D8, we can produce the human drug metabolite, 2-hydroxyibuprofen 6,o napreparative scale with 96 %i solated yield (Scheme 1).
Conversions and TTNs of the different P450 variantsf or ibuprofen, as well as selectivities in the form of product ratios for2 ' -versus 3'-hydroxylation, are presented in Table 1 . The first variant 22A3, which differed from 13C9R1 by as ingle F162I substitution,s howed increased activity and TTN on both, naproxen and ibuprofen. Increased activity on ibuprofen correlated with improvements on naproxen for variants 13C9R1 to W7D8 ( Figure 1B ). Only M185K in variant X3H1 increased the activity on naproxen, but not on ibuprofen.
Most mutations are deleterious, which is also true for mutations that increase activity.T he thermostability was measured using the T 50 value. During the course of directed evolution, T 50 decreased from 54 to 45.5 8Cf or 16G2 before increasing again to 48.7 8C ( Figure 1 ). As ac onsequence of its decreased stability, variant 16G2 catalyzed fewer TTNs than its parent 22A3, even thoughi tw as more active in the screen (Figure 1) . Notably,t he T 50 nadir corresponded to the point at which it becameh ard to detect improved mutants (only 1i mproved variant identified in 6000 clones), which is anecdotal evidence in support of the observation made by Bloom et al. that aT 50 of 47 8Ci sam inimum threshold for P450 BM3 variants to accept furtherm utationsu nder these experimental conditions. [17] Subsequent variant W7D8 showed improved activity,t hermostability,a nd TTN. The most active variants, X3H1 andW 7D8, allowed conversion of the NSAIDs naproxen and ibuprofen with TTNs of 1000and 600, respectively.
As the variants catalyzed more turnoverso nn aproxen, a second product began to appear in the bioconversions. The new product had an absorption spectrumv ery different from www.chemcatchem.org that of naproxen and desmethylnaproxen (Supporting Information, Figure S1 ). The concentration of the new product strongly correlated with the activity on naproxen. The progression of the reaction, and the analysis of the reactionstarting from desmethylnaproxen, suggested that the new product was formed in ac onsecutive rather than ap arallel reaction (see the Supporting Information, Figure S1 ). Isolation and characterization by using HPLC-MS and 1 H, 13 C, and 2D-NMRs pectroscopy revealed that the product was (S)-2-(6-hydroxy-5,8-dioxo-5,8-dihydronaphthalene-2-yl)propanoic acid 4.
We propose that desmethylnaproxen was hydroxylated at position5 (Scheme 1, 3) , as in the Elbs-oxidation of b-naphthol with persulfate, [24] and that the phenolic product was further oxidizedt oq uinone by air [25] or superoxide.
[26] Alternative paths for the oxidation of 2-hydroxynaphthalene to a2 -hydroxyl-1,4-naphthoquinone have been described. [25, 27] The naproxen bioconversion could be controlled to produce 82 % (43 %i solated yield) desmethylnaproxen, because the aromatic hydroxylation is significantly slower than the demethylation.
We also tested the variants for activity on 1-naphthalene acetic acid (NAA;F igure 2A, 8), whichi ss tructurally relatedt o naproxen.N AA is ap lant hormonei nt he auxin family and an ingredient in many commercialp lant rooting horticultural products.P arent 13C9R1d isplayed al ow,b ut detectable activity on 8,w hich was increased slightly in the early intermediate 22A3. Starting with 16G2, however,v ariantsl ost their activity on 8,s pecializing insteado n1and 5.V ariantsw ith increased activity on NAA were found as the libraries weres creened on NAA, and these variants,S 6C4 and S31A, had mutationsd ifferent from those in 16G2. Activity on NAA was furtheri mproved by recombination and error-prone PCR.F igure 2B illustrates the specialization of variants screened for activity on 1 and 8.
Early intermediate 22A3 is the last common ancestor with improvedactivity on all three substrates.
We thus extended the drug metabolite repertoire of P450 BM3 variants to include weakly acidic substrates of human CYP2C9. MutationsR 398H and M185K exhibited the largesta ctivity improvements. M185K was the only mutation that increased activity on naproxen,b ut not ibuprofen. R398H was as urprising mutation,b ecause R398 is highly conserved and stabilizes the heme propionate through bidentate hydrogen bonding with the propionate side chain of the heme. [28] Therefore, the mutation of R398 to histidine in W7D8 is likely to influence the conformation of the heme propionates or even the overall heme orientation, although we conjecture that H398 retains one hydrogen bond to the propionate as shown in the modeled histidine rotamer (Supporting Information, Figure S3 ). Another potential disruptive effect of R398H would be ac onformational change of the loop followingt he B' helix, caused by the loss of hydrogen bonds to the backbone carbonyls of L86 and S89. Finally,t he proximity of R398H to previouslya ccumulatedm utations L75R and H100R ( Figure S3 ) suggests possible interactions mediated by ac onformational change of the heme or the loop following the B' helix.
Structure of an early intermediate in the directed evolution
We crystallized the heme domains of the early intermediates 13C9 and2 2A3 to better understand the effect of the L75R mutation in P450 BM3 and to explore the structural basis of their broadened substrate ranges. Specifically,w ew anted to determine whether the resulting R75 in P450 BM3 played ar ole similar to R108 in human CYP2C9, in which the arginines ide chain formed hydrogen bonds directly with the carboxyl group of the substrate, as shown in the X-ray structure of the complex with flurbiprofen ( Figure 3A) . [29] Overall, the P450 BM3 variant 22A3 carries 18 mutations in the heme domain and is, to the best of our knowledge, the most highly mutated P450 BM3 variant, for which the structure has been determined to date. Seven of these mutations were accumulated during directed evolution for increased thermostability (highlighted in red in the Supporting Information, Figure S2 ). Four mutations (L75R, F87A, H100R, F107L)w ere located within 8 of the heme; among them is the key L75R mutation.T he other three mutations originated from previous directed evolution for an increasedp eroxygenase activity. [30] Most mutations are far (> 8) from the active site.
We prepared 22A3 crystalst hat diffracted to 3.1 ( Supporting Information, Ta ble S5). The unit cell contained two copies of the protein (chain Aand chain B). The destabilizing influence of the L75R mutation [17] was immediately apparent from the 22A3 crystal structure, as it increased local flexibility.F or chain A, the entire B' helix containing the mutation was unresolved. For chain B, helix B' and R75 were resolved, but with exceptionally high Bfactors ( Figure 4) for the entire region, suggesting that the region was not well determined. This usually reflects imperfect orderi nt he crystal, indicating high flexibility,f or example, in less structured regions. Introduction of R75 into the predominantly hydrophobic actives ite of P450 BM3 Figure 2 . A) Substrate 1-naphthalene acetic acid 8 used in this study.B )Phylogeny of evolved variants and substrates on which the variants showed increased activity (1, 5,a nd/or 8). Variants shown in light grey were found by using as creen for naproxen activity.V ariants in dark grey werefound by using as creen for improved activity on 8.2 2A3 is the last commonancestor with an improved activity on 1, 5,a nd 8.F irst specialization:V ariant 16G2 exhibited an improved activity on 1 and 5,b ut ad ecreased activity on 8. The samelibrary, however,c ontainedv ariants with improved activity on 8 (S6C4 and S31A7);t hese variants were furthero ptimized (ReF2 and Y5A7). Second specialization:V ariant X3H1 has as ignificantly improved activity on 1 and areduceda ctivity on 5.T he question mark suggests that the same library may contain variants with an improved activity on 5,b ut verificationis not possible without as uitable high-throughput screen.
provided the basis for novel albeit rather nonspecific acceptance of negatively charged substrates. L75R, however,d isrupted the local structure, resulting in ar educed stability of the protein and an increased flexibility of the B' helix close to the active site. This flexibility may contributet ot he broad substrate tolerance [31] in 13C9 and 22A3. Subsequentr ounds of directed evolution revealed mutations that improved accommodation of these drastic changes, resulting in increased thermostabilitya sw ell as specificity for the target substrate.
Modeling naproxen into 22A3
HumanC YP2C9h as ap reference for weakly acidic ligands, [15] and its active-site residue R108 formsh ydrogen bonds with the anionic ligand moiety ( Figure 3A) . [29, 32] In the substratebinding pocket of P450 BM3 ,R 75 could play as imilarr ole in the interaction of the bacterial P450 with naproxen. [17] To assess the role of the L75R mutation, we modeled potentialt ransition state conformations for the naproxenh ydroxylation in the 22A3 active site by using the ROSETTA energy function. [33] After fixing the bond lengths and angles for FeÀOÀHÀR, [34] we exhaustively searched al arge number of discrete substrate orientations.P otential docking positions that did not clash with the protein backbone were furthero ptimized by allowing the sidechains of the protein to relax. [35] For each resulting model, we calculated the ROSETTAs core. The most favorable conformation of the transition state of naproxen placed the carboxylate moiety towardt he entrance of the binding channel. In this general orientation,s ubstrate binding displaced R75 and L437 ( Figure 3B )a nd the R75 guanidinium group could not form a direct hydrogen bond to the naproxen carboxylate, butinstead remained associated with the heme propionate.
Thus, we propose that R75 in P450 BM3 plays ar ole different from that of R108 in CYP2C9. Instead of forming direct hydrogen bonds, R75 seems to compensate the negative charge in a more general way.B yi ntroducing favorable electrostatic interactions,t he buried positive chargeo fR 75 decreasest he penalty for desolvating naproxen. In contrast, modeling suggests that K185 could interactd irectly with naproxen in the transition state, depending on the exact position of helix F.
Conclusions
Drug metabolites can imposet heir own pharmacological, toxicological, and physiological effects, leading to complications that have resulted in the withdrawal of severald rugs from the Figure 3 . Charge compensation in the human P450 CYP2C9 and its bacterial mimic from P450 BM3 .A)CYP2C9 (pdb 1RO9, purple) in ac omplex with flurbiprofen. R108 (cyan) formed hydrogen bonds with the carboxyl groupo ft he propionate side chain. Hydroxylation occurs at the 4'-positionpointing toward the heme. B) Naproxen conformers were docked to the 22A3 crystal structure (white backbone) and positioned in atransition state geometry relative to the heme (blue spheres) of ah ypothetical compoundIoxygen (red sphere). The most favorable naproxen poses (orange) induced relaxation of L437 and R75 (green).Ina ll cases, the favorable naproxen poses extended along the binding channel, and R75 was unable to form ad irect hydrogen bond to naproxen. market. [3] Mostd rugs are substrates for the hepatic P450 oxidases. In vivo CYP2C9 has ap reference fors ubstrates with weak acidity [15] like many NSAIDs. Up to now,t here has been no reported P450 BM3 variant exhibiting good activity on these chargedm olecules. In the current study,w er eport two P450 BM3 variants,X 3H1 and W7D8, which allow conversion of the NSAIDs naproxen and ibuprofen with TTNs of 1000a nd 600, respectively,a nd can be used to produce knowna nd novel drug metabolites on apreparative scale.
From crystal structure analysisa nd modeling, we conclude that the mode of substrate binding in the early,p romiscuous P450 BM3 variants differs from that of human CYP2C9. The negative chargea nd drastic increasei nf lexibility in the neighborhood of L75R may be the structuralb asis for the broadened substrate tolerance.
There is ac lear stability-function tradeoff for the active site mutation L75R. L75R 'damaged' the enzyme, producing ad estabilized variant that wasn ot very efficient on any substrate, but had gained ab asal activity on negatively charged substrates. This basal activity subsequently served as as tarting point for further directed evolution. Such ap rogression corresponded to previously observed enzyme 'promiscuity',t hat appeared during early rounds of directed evolution with lowa ctivities, and that is followed by respecialization at higher activities.
[36] However,t he stability-function tradeoff is not obligatory,a sw as apparent during later directed evolution rounds in which mutations were found that increased both stabilitya nd activity.A lthough such mutationsa re generally rare, we found them repeatedly when screening near the apparent stability threshold, where stabilizing mutations can positivelya ffect activity integrated over the screening period.
Experimental Section
All experimental details and protocols are described in the Supporting Information. Data collection and refinement statistics of the crystal structure are also appended. Coordinates and structure factors have been deposited in the Protein Data Bank (www.pdb.org) with accession number 3QI8.
